Skip to content

Effect of CIT on immunity in healthy individuals

Evaluation of the effect of CIT on innate and adaptive immune responses in healthy individuals

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/030139
Enrollment
30
Registered
2020-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: CIT: CIT is a tablet composed of formulation Triphala Guggul and herbs like Tinospora cordifolia, Curcuma longa, Rubia cordifolia, Plumbago zeylanica, Piper longum, Piper nigrum and Zin

Sponsors

Charak Pharma Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Individuals of either sex in the age group 18-35 years 2.Individuals ready to abide by trial procedures and give written informed consent

Exclusion criteria

Exclusion criteria: 1.Individuals with known history of usage of herbal medications/ nutritional supplements/ multivitamin supplements/ pre and probiotic supplementation/ available market medications for immunity within past 30 days for any indication. 2.Individuals with known history of thyroid disorders, cardiac, liver or renal pathologies. 3.Pregnant and lactating females 4.Haemoglobin 5.Liver function tests > 2.5 times the upper normal limits 6.Renal function tests > 1.5 times the upper normal limits.

Design outcomes

Primary

MeasureTime frame
1.10% more improvement in innate immunity assessed as Interferon (IFN gamma) in CIT group as compared to placebo group 2.10% more increase in proportion of cells involved in cell mediated immunity viz. CD4 and CD8 in CIT group as compared to placebo group 3.10% more increase in functional capacity of Mononuclear cells in CIT group as compared to placebo group 4.10% more improvement in perceived stress and quality of life in CIT group as compared to placebo group Timepoint: Baseline, 4 weeks and 8 weeks- IFN gamma, perceived stress, quality of life Baseline and 8 weeks- CD4, CD8 counts and functional capacity

Secondary

MeasureTime frame
1.10% more improvement in anti-oxidation status of red blood cells in CIT group as compared to placebo group 2.Safety of the study drug throughout the study Timepoint: Baseline and 8 weeks- Anti-oxidation status of red blood cells in CIT group as compared to placebo group Screening and 8 weeks- Safety of the study drug

Countries

India

Contacts

Public ContactSupriya Bhalerao

Interactive Research School for Health Affairs, Bharati Vidyapeeth Deemed to be University

supriya.bhalerao@gmail.com24366920

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026